$235M GSK Win Stays, But Fed. Circ. Tells Generics To Relax
By Dani Kass · August 5, 2021, 10:27 PM EDT
A split Federal Circuit panel has once again revived a $235 million verdict against Teva for inducing infringement of GlaxoSmithKline's heart disease drug Coreg, although the panel's revised decision Thursday warned...
To view the full article, register now.